Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nisoldipine in severe ischaemic left ventricular dysfunction

H Pouleur1, M F Rousseau

  • 1Department of Physiology and Pharmacology, University of Louvain, Brussels, Belgium.

European Heart Journal
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a) levels are doubled in left-handed patients with diabetes.

Diabetes & metabolism·2018
Same author

Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure.

Clinical biochemistry·2014
Same author

Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.

Clinica chimica acta; international journal of clinical chemistry·2013
Same author

What is the phenotype of patients with gastrointestinal intolerance to metformin?

Diabetes & metabolism·2013
Same author

Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure.

Clinical biochemistry·2012
Same author

Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure.

Journal of endocrinological investigation·2012
Same journal

Disrupted erythrocyte S1P-eNOS axis promotes hypoxia, hypertension and fibrosis in obstructive sleep apnoea-hypopnoea syndrome.

European heart journal·2026
Same journal

Stroke and systemic embolism following AF ablation: importance of global registries.

European heart journal·2026
Same journal

Update on lipoprotein(a): the rising star in residual lipid risk.

European heart journal·2026
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
See all related articles

Calcium antagonists like verapamil may worsen heart failure. However, newer drugs like nisoldipine show promise for improving exercise tolerance in patients with ischemic left ventricular dysfunction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Calcium antagonists (e.g., verapamil, diltiazem, nifedipine) have historically raised concerns regarding their use in severe cardiac dysfunction due to potential worsening of congestive heart failure.
  • Advancements in understanding drug pharmacology, pharmacokinetics, and neuro-humoral effects have led to improved calcium antagonist molecules.

Purpose of the Study:

  • To evaluate the efficacy and safety of newer calcium antagonists, specifically nisoldipine, in patients with left ventricular dysfunction.
  • To explore the potential benefits of combining nisoldipine with ACE-inhibitors for managing ventricular dysfunction.

Main Methods:

  • Clinical trials investigating nisoldipine in patients with ischemic left ventricular dysfunction.
  • Studies assessing the combined effects of nisoldipine and ACE-inhibitors.

Related Experiment Videos

Main Results:

  • Nisoldipine demonstrated promising results in patients with ischemic left ventricular dysfunction, leading to improved exercise tolerance.
  • Diastolic filling improvements were observed, potentially linked to enhanced function in chronically ischemic areas.

Conclusions:

  • Nisoldipine shows potential benefits for patients with ischemic left ventricular dysfunction, improving symptoms and exercise capacity.
  • Further trials are needed to determine if nisoldipine, alone or in combination with ACE-inhibitors, can slow the progression of ventricular dysfunction.